Roche Assay Okayed to Assist Novartis Drug in Lung Cancer Detection

Roche Assay Okayed to Assist Novartis Drug in Lung Cancer Detection

Lung cancer remains the leading cause of cancer deaths, with more than 1.6 million deaths worldwide each year.1 "With the FDA's approval of the expanded use of the Ventana ALK (D5F3) CDx Assay to determine which lung cancer patients are eligible for Zykadia, we are helping clinicians and t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical Processing 2017-06
1. Verfasser: AG, Roche Holding
Format: Artikel
Sprache:eng
Schlagworte:
FDA approval
Lung cancer
Pharmaceutical industry
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lung cancer remains the leading cause of cancer deaths, with more than 1.6 million deaths worldwide each year.1 "With the FDA's approval of the expanded use of the Ventana ALK (D5F3) CDx Assay to determine which lung cancer patients are eligible for Zykadia, we are helping clinicians and their patients identify additional treatment options for non-small cell lung cancer," said Ann Costello, head of Roche Tissue Diagnostics.
ISSN:1049-9156